Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996